Login
$CTMX
$2.02 +$0.03 (1.76%) After hours

$CTMX SEC Filings

Filed On Filing
10 Nov 2026 SCHEDULE 13G
05 Nov 2026 8-K: Results of Operations and Financial Condition

- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer -

05 Nov 2026 10-Q
28 Oct 2026 SCHEDULE 13G/A
16 Oct 2026 Form 4/A: McCarthy Sean A., Director

Received 101,793 shares by exercise or conversion ($162K) · Sold 101,793 shares ($462K)

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
07 Aug 2026 SCHEDULE 13G
06 Aug 2026 S-8
06 Aug 2026 8-K: Results of Operations and Financial Condition

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

06 Aug 2026 10-Q
05 Aug 2026 Form 4: Carvajal Alejandra, Chief Legal Officer

Received 100,000 shares as a grant or award · Granted 450,000 Stock Option (Right to Buy)

05 Aug 2026 Form 3: Carvajal Alejandra, Chief Legal Officer

No securities owned

03 Aug 2026 SCHEDULE 13G
30 Jul 2026 Form 4: Fuchs Charles S., Director

Granted 118,000 Stock Option (Right to Buy)

30 Jul 2026 Form 3: Fuchs Charles S., Director

No securities owned

27 Jul 2026 SCHEDULE 13G
27 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

22 Jun 2026 Form 4: Su Zhen, Director

Granted 59,000 Stock Option (Right to Buy)

22 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

1.1 Purposes. This CytomX Therapeutics, Inc. Amended and Restated 2015 Equity Incentive Plan, as amended by the Board on March 18, 2026 (this “Plan”), is effective as of the date the stockholders of the Company approve this Plan. The pur...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support